Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apollomics Inc. (APLM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Stock Market. Apollomics files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, detailing its clinical-stage oncology business, financial condition, governance changes and material events.
Through these filings, investors can review annual reports on Form 20-F for comprehensive information on Apollomics’ oncology pipeline, including vebreltinib (APL-101) and other disclosed programs, risk factors, financial statements and notes, as well as descriptions of collaborations and licensing arrangements. Interim Form 6-K reports furnish updates on topics such as PIPE financings, reverse share split implementation, auditor changes, Nasdaq listing status, operational continuity plans, and settlements of matters like the Cayman Litigation involving minority investors.
Filings also describe Apollomics’ clinical and strategic decisions, including the conclusion of the uproleselan program after an unfavorable Phase 3 bridging trial in China, termination of the APL-122 development and license agreement with Edison Oncology Holding Corporation, and the company’s focus on advancing vebreltinib through global Phase 2 trials. Disclosures on internal control over financial reporting, changes in independent registered public accounting firms, and remediation of previously identified material weaknesses are available in the same record.
On Stock Titan, Apollomics filings are updated as they are posted to EDGAR, and AI-powered summaries help explain the key points in complex documents. Users can quickly see what each 6-K or 20-F covers, from financial results and impairment charges to listing determinations and settlement agreements, without reading the full text immediately. For those researching APLM, this page is a central resource for understanding how Apollomics presents its oncology strategy, financial performance and corporate governance to regulators and investors.
Apollomics Inc. disclosed initial holdings for Chief Financial Officer Lin Peter Kuan-How, showing 40,000 Restricted Stock Units tied to Class A Ordinary Shares. The RSUs vest in stages: 10,000 shares vested upon grant on February 9, 2026, with an additional 10,000 vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is reported as directly owned.
Apollomics Inc. registers the resale of 279,775 Class A ordinary shares for selling securityholders.
The shares were issued under subscription agreements dated September 2, 2025 and are being registered to permit the selling securityholders to offer and sell the PIPE Shares from time to time after effectiveness. The Company will not receive proceeds from resales and will pay registration expenses.
Apollomics Inc. reports that it has terminated its development and license agreement with Edison Oncology Holding Corporation covering APL-122, an oral, irreversible pan-ErbB inhibitor targeting EGFR, HER2 and HER4 for ErbB-positive cancers with central nervous system metastases. The company states it ended the collaboration effective immediately based on Edison’s failure to meet certain material performance and reporting obligations and is disputing any outstanding payment claims.
Apollomics indicates that it does not expect this termination to have a material adverse effect on its overall financial condition or results of operations, and notes that information about the termination is being incorporated by reference into its existing registration statements.
Apollomics Inc. (APLM) reported that it has entered into a settlement agreement to fully resolve legal proceedings in the Grand Court of the Cayman Islands brought by two minority investors. The dispute arose from claims filed on July 22, 2024, related to the requested redemption of certain preferred shares before Apollomics completed its 2023 public merger with Maxpro Capital Acquisition Corporation. A stay order had previously been issued on September 12, 2025, and the parties are now in the process of submitting the settlement for court approval to conclude the litigation. The information about this settlement is also being incorporated by reference into Apollomics’ registration statements on Form S-8 and Form F-3.
Apollomics, Inc. reported a change in its Board of Directors. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board, with the company stating that his resignation was not related to any disagreement with the company.
On the same date, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the resulting vacancy and will also serve on the Audit Committee and the Nominating and Corporate Governance Committee. Following recent appointments, the Board now has seven members, five of whom are described as independent directors.
Dr. Huang brings experience in biotechnology investment, corporate governance, and R&D, including roles at Maxpro Ventures, Diamond Biofund, Fubon Securities, and multiple research institutions. The company also issued a press release on November 17, 2025 describing these board and committee changes, which is included as an exhibit.
Apollomics Inc. reported it has received US$3,900,000 from LaunXP related to their collaboration on vebreltinib in Asia (excluding mainland China, Hong Kong and Macau). The company stated the agreement remains in full force and effect, with both parties continuing to perform their obligations. Apollomics also noted this update is incorporated by reference into its registration statements on Form S-8 and Form F-3.
Apollomics Inc. changed its independent auditor and confirmed continued Nasdaq listing. On October 13, 2025, the Audit Committee dismissed Grant Thornton LLP and approved Marcum Asia CPAs LLP as auditor, effective immediately. Grant Thornton’s 2023 and 2024 reports had no adverse opinions, and the Company reports no disagreements through October 13, 2025. A material weakness disclosed as of December 31, 2023 was remediated during 2024.
On October 14, 2025, Nasdaq notified the Company it is in compliance; the appeal hearing was cancelled and the securities will remain listed.
Apollomics Inc. provided an operational continuity update, reversing prior plans to wind up after receiving $4.1 million in PIPE funding and appointing a new board and management team. The company will continue its global Phase 2 SPARTA trial of APL-101 (vebreltinib), a targeted therapy with positive results across more than 280 patients.
Management notified CROs and licensing partners of the transition and continuation of trials; contracts with current CROs are fully paid and up to date. Apollomics aims to support regulatory submissions in the U.S., EU and other markets, and plans to leverage Chinese approvals for MET-amplified NSCLC and GBM via its partner to pursue submissions in Southeast Asia, the Middle East and other regions. The company has 12 full-time employees and expects headcount to reach 15 by October 31, 2025, with a planned shift of roles from China to the U.S. and Taiwan.
Apollomics Inc. (APLM) disclosed two press-release exhibits: one announcing receipt of a Nasdaq delisting determination letter and a second stating the company has completed filing an appeal of the Nasdaq delisting order. The filings are attached as Exhibits 99.1 and 99.2. The current report is dated September 25, 2025 and is signed by Peter Lin, Chief Financial Officer. The document does not include financial results, specific reasons for the delisting determination, timelines for the appeal process, or details about potential remedies.